

REFLECT SCIENTIFIC INC  
Form 10-Q  
May 15, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 10-Q**

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2017

or

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number 000-31377

**REFLECT SCIENTIFIC, INC.**

(Exact name of registrant as specified in its charter)

**Utah**

**87-0642556**

(State or other jurisdiction of

(IRS Employer Identification No.)

incorporation or organization)

**1266 South 1380 West Orem, Utah 84058**

(Address of principal executive offices) (Zip Code)

**(801) 226-4100**

(Registrant's telephone number, including area code)

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definition of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.

Large Accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files).

Yes [X] No [ ]

**Applicable Only to Issuers Involved in Bankruptcy Proceedings During the Preceding Five Years:**

Indicate by check mark whether the Registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

Not applicable.

**Applicable Only to Corporate Issuers:**

Indicate the number of shares outstanding of each of the Registrant's classes of common equity, as of the latest practicable date.

**Class**

**Outstanding as of May 15, 2017**

65,401,086 shares of \$0.01 par value common stock on May 15, 2017



**TABLE OF CONTENTS**

**PART I FINANCIAL INFORMATION**

Item 1:	Financial Statements	
	Condensed Consolidated Balance Sheets	
	As of March 31, 2017 (unaudited), and December 31, 2016	5
	Condensed Consolidated Statements of Operations	
	For the three months ended March 31, 2017 and 2016 (unaudited)	7
	Condensed Consolidated Statements of Cash Flows	
	For the three months ended March 31, 2017 and 2016 (unaudited)	8
	Notes to Condensed Consolidated Financial Statements	9
Item 2:	Management's Discussion and Analysis of Financial Condition and Results of Operations	13
Item 3:	Quantitative and Qualitative Disclosure about Market Risk	15
Item 4:	Controls and Procedures	16

**PART II OTHER INFORMATION**

Item 1:	Legal Proceedings	16
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	16
Item 3:	Defaults Upon Senior Securities	17
Item 4:	Mine Safety Disclosure	17
Item 5:	Other Information	17
Item 6:	Exhibits	17
	Signatures	19



Part I - FINANCIAL INFORMATION

Item 1. Financial Statements

Reflect Scientific, Inc.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

March 31, 2017

The financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. However, in the opinion of management, all adjustments (which include only normal recurring accruals) necessary to present fairly the financial position and results of operations for the periods presented have been made. These financial statements should be read in conjunction with the accompanying notes, and with the historical financial information of the Company.







## REFLECT SCIENTIFIC, INC.

## Condensed Consolidated Balance Sheets

ASSETS

	March 31, 2017 (Unaudited)	December 31, 2016
<b>CURRENT ASSETS</b>		
Cash	\$ 233,589	\$ 263,964
Accounts receivable, net	61,328	73,424
Inventory, net	232,458	226,967
Prepaid assets	3,100	3,100
Total Current Assets	530,475	567,455
<b>FIXED ASSETS, NET</b>	-	-
<b>OTHER ASSETS</b>		
Intangible assets, net	-	-
Goodwill	60,000	60,000
Deposits	3,100	3,100
Total Other Assets	63,100	63,100
<b>TOTAL ASSETS</b>	<b>\$ 593,575</b>	<b>\$ 630,555</b>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**REFLECT SCIENTIFIC, INC.**

Condensed Consolidated Balance Sheets (Continued)

LIABILITIES AND STOCKHOLDERS EQUITY

	March 31, 2017 (Unaudited)	December 31, 2016
<b>CURRENT LIABILITIES</b>		
Accounts payable and accrued expenses	\$ 24,246	\$ 58,968
Customer deposits	130	-
Income taxes payable	100	100
Total Current Liabilities	24,476	59,068
Total Liabilities	24,476	59,068
<b>COMMITMENTS AND CONTINGENCIES</b>	-	-
<b>STOCKHOLDERS EQUITY</b>		
Preferred stock, \$0.01 par value, authorized 5,000,000 shares; No shares issued and outstanding	-	-
Common stock, \$0.01 par value, authorized 100,000,000 shares; 65,401,086 and 65,401,086 issued and outstanding, respectively	654,010	654,010
Additional paid in capital	19,566,472	19,566,472
Accumulated deficit	(19,651,383)	(19,648,995)
Total Stockholders Equity	569,099	571,487
<b>TOTAL LIABILITIES AND STOCKHOLDERS EQUITY</b>	<b>\$ 593,575</b>	<b>\$ 630,555</b>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**REFLECT SCIENTIFIC, INC.**

## Condensed Consolidated Statements of Operations

(Unaudited)

	For the Three Months Ended	
	March 31,	
	2017	2016
REVENUES	\$ 255,915	\$ 373,964
COST OF GOODS SOLD	90,028	107,180
GROSS PROFIT	165,887	266,784
OPERATING EXPENSES		
Salaries and wages	105,280	107,207
Rent expense	8,578	8,609
Research and development expense	11,630	26,922
General and administrative expense	42,787	88,013
Total Operating Expenses	168,275	230,751
NET OPERATING INCOME (LOSS)	(2,388)	36,033
OTHER EXPENSE		
Interest expense	-	(143)
Total Other Expense	-	(143)
NET INCOME (LOSS) BEFORE TAXES	(2,388)	35,890
Provision for income taxes	-	-
NET INCOME (LOSS)	\$ (2,388)	\$ 35,890
NET INCOME (LOSS) PER SHARE BASIC	\$ (0.00)	\$ 0.01
NET INCOME (LOSS) PER SHARE DILUTED	\$ (0.00)	\$ 0.01
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING BASIC AND DILUTED	65,401,086	60,958,514

The accompanying notes are an integral part of these condensed consolidated financial statements.



**REFLECT SCIENTIFIC, INC.**

## Condensed Consolidated Statements of Cash Flows

(Unaudited)

For the

Three Months Ended

March 31,

	2017		2016
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Net income (loss)	\$ (2,388)	\$	35,890
Adjustments to reconcile net income (loss) to net cash used in operating activities:			
Amortization	-		4,453
Changes in operating assets and liabilities:			
Accounts receivable	12,096		(73,677)
Inventory	(5,491)		6,912
Accounts payable and accrued expenses	(34,722)		(35,321)
Customer deposits	130		(45,378)
Net Cash used in Operating Activities	(30,375)		(107,121)
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>	-		-
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Payments on short-term lines of credit	-		(2,828)
Net Cash used in Financing Activities	-		(2,828)
<b>NET INCREASE (DECREASE) IN CASH</b>	(30,375)		(109,949)
<b>CASH AT BEGINNING OF PERIOD</b>	263,964		292,087
<b>CASH AT END OF PERIOD</b>	\$ 233,589	\$	182,138

**SUPPLEMENTAL CASH FLOW INFORMATION:**

## Cash Paid For:

Interest	\$	-	\$	143
Income taxes	\$	-	\$	-

The accompanying notes are an integral part of these condensed consolidated financial statements.

**REFLECT SCIENTIFIC, INC.**

Notes to the Condensed Consolidated Financial Statements

March 31, 2017

(Unaudited)

NOTE 1 -

**BASIS OF FINANCIAL STATEMENT PRESENTATION**

The accompanying unaudited condensed consolidated financial statements have been prepared by the Company pursuant to accounting principles generally accepted in the United States of America. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted in accordance with rules and regulations of the Securities and Exchange Commission. The information furnished in the interim condensed consolidated financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements. Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim condensed consolidated financial statements be read in conjunction with the Company's most recent audited consolidated financial statements and notes thereto included in its December 31, 2016 financial statements. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017.

NOTE 2 -

**ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**ORGANIZATION AND LINE OF BUSINESS:**

Cole, Inc. (the Company) was incorporated under the laws of the State of Utah on November 3, 1999. The Company was organized to engage in any lawful activity for which corporations may be organized under the Utah Revised Business Corporation Act. On December 30, 2003 the Company changed its name to Reflect Scientific, Inc.

Reflect Scientific designs, develops and sells scientific equipment for the Life Science and Manufacturing industries. The Company's business activities include the manufacture and distribution of unique laboratory consumables and disposables such as filtration and purification products, customized sample handling vials, electronic wiring assemblies, high temperature silicone, graphite and vespel/graphite sealing components for use by original equipment manufacturers ( OEM ) in the chemical analysis industries, primarily in the field of gas/liquid chromatography.

The Company's chemical detector products serve the analytical instrumentation sector of the Life Sciences market. These optically based chemical detection instruments provide a cost-effective, high-performance alternative for original equipment manufacturers (OEM). One major use for these detectors is the analysis of whole blood for metabolic diseases.

**SIGNIFICANT ACCOUNTING POLICIES:**

**PRINCIPLES OF CONSOLIDATION:** The accompanying consolidated financial statements include the accounts of Reflect Scientific, Inc. and its wholly owned subsidiaries, Cryometrix and Julie Martin Scientific Technology. Intercompany transactions and accounts have been eliminated in consolidation.

**USE OF ESTIMATES:** The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.

**REVENUE RECOGNITION:** Revenue is only recognized on product sales once the product has been shipped to the customer, persuasive evidence of an agreement exists, the price is fixed or determinable, and collectability is reasonably assured. The Company sells its products in both the US and internationally through direct sales and independent distributors.

**ACCOUNTS RECEIVABLE:** Accounts receivables are presented net of an allowance for doubtful accounts. The Company maintains allowances for doubtful accounts for estimated losses. The Company reviews the accounts receivable on a periodic basis and makes general and specific allowances when there is doubt as to the collectability of individual balances. In evaluating the collectability of individual receivable balances, the Company considers many factors, including the age of the balance, a customer's historical payment history, its current credit-worthiness and current economic trends. Accounts are written off after exhaustive efforts at collection. At March 31, 2017 and December 31, 2016, the Company had accounts receivable of \$61,328 and \$73,424, respectively. At March 31, 2017 and December 31, 2016 the allowance for doubtful accounts was \$4,000 and \$4,000, respectively.

**INVENTORY:**

Inventories are presented net of an allowance for obsolescence and are stated at the lower of cost or market value based upon the average cost inventory method. The Company's inventory consists of parts for scientific vial kits, refrigerant gases, components for detectors and ultra-low temperature freezers which it builds and other scientific items. At March 31, 2017, inventory was made up of \$255,110 of finished goods, less an allowance for obsolescence of \$22,652. At December 31, 2016, inventory was comprised of \$249,619 of finished goods, less an allowance for obsolescence of \$22,652. There were no raw materials or work in progress for either period presented.

**INTANGIBLE ASSETS:** Costs to obtain or develop patents are capitalized and amortized over the life of the patents. Patents are amortized from the date the Company acquires or is awarded the patent over their estimated useful lives, which range from 5 to 15 years. An impairment charge is recognized if the carrying amount is not recoverable and the carrying amount exceeds the fair value of the intangible assets as determined by projected discounted net future cash flows. The Company's analysis did not indicate any impairment of intangible assets as of March 31, 2017.

**GOODWILL:** Goodwill represents the excess of the Company's acquisition cost over the fair value of net assets of the acquisition. Goodwill is not amortized, but is tested for impairment annually, or when a triggering event occurs. As described in ACS 360, the Company has adopted the two step goodwill impairment analysis that includes quantitative factors to determine whether it is more likely than not that

the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. A fair-value-based test is applied at the overall Company level. The test compares the estimated fair value of the Company at the date of the analysis to the carrying value of its net assets. The analysis also requires various judgments and estimates, including general and macroeconomic conditions, industry and the Company's targeted market conditions, as well as relevant entity-specific events, such as a change in the market for the Company's products and services. After considering the qualitative factors that would indicate a need for interim impairment of goodwill and applying the two-step process described in ASC 360, management has determined that the value of Company's assets is not more likely than not less than the carrying value of the Company including goodwill, and that no impairment charge needs be recognized during the reporting periods.

**RESEARCH AND DEVELOPMENT EXPENSE** - The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board's Accounting Standard Codification Topic 730 "Research and Development". Under ASC 730, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred.

**EARNINGS PER SHARE:** The computation of basic earnings per share of common stock is based on the weighted average number of shares outstanding during the period. Diluted EPS is computed by dividing net earnings by the weighted-average number of common shares and dilutive common stock equivalents during the period. Common stock equivalents are not used in calculating dilutive EPS when their inclusion would be anti-dilutive. At March 31, 2017 and 2016, the Company had no common stock equivalents.

**RECENT ACCOUNTING PRONOUNCEMENTS** In January 2017, the Financial Accounting Standards Board ( FASB ) issued Accounting Standards Update ( ASU ) 2017-04, *Intangibles - Goodwill and Other (Topic 350)*. This ASU was issued to simplify the annual goodwill impairment assessment process. Currently, the first step of the impairment test requires an entity to compare the fair value of the reporting unit with its carrying value, including goodwill. If, as a result of this analysis, the entity concludes there is an indication of impairment in a reporting unit having goodwill, the entity is required to perform the second step of the impairment analysis, determining the amount of goodwill impairment to be recorded. The amount is calculated by comparing the implied fair value of the goodwill to its carrying amount. This exercise requires the entity to allocate the fair value determined in step one to the individual assets and liabilities of the reporting unit. Any remaining fair value would be the implied fair value of goodwill on the testing date. ASU 2-17-04 eliminates the second step of the impairment analysis. Accordingly, if the first step of a quantitative goodwill impairment analysis performed after adoption of this ASU indicates that the fair value of a reporting unit is less than its carrying value, the goodwill of that reporting unit would be impaired to the extent of that difference. The Company must adopt this ASU in 2020, but early adoption is permitted. However, if there is an indication of potential impairment of goodwill as a result of an annual impairment assessment prior to 2020, the Company will evaluate the impact of ASU 2017-04 and could elect to early adopt this ASU.





In March 2017, the FASB issued ASU 2017-07, *Compensation - Retirement Benefits (Topic 715)*. This ASU was issued to improve the presentation of net periodic pension and other postretirement benefit costs. The Company must adopt this ASU beginning January 1, 2018. The Company does not currently have a pension or retirement plan to which it contributes and therefore believes it will not have an impact on its financial statements and statements of operations.

In March 2017, the FASB issued ASU No. 2017-08, *Receivables - Nonrefundable Fees and Other Costs (Topic 310-20)*. The ASU amends the amortization period for certain purchased callable debt securities held at a premium. The update requires premiums to be amortized over the period to the earliest call date. The new standard has an effective adoption date of January 1, 2019. Early adoption is permitted. The Company is analyzing the impact of this new standard.

The Company has reviewed all other recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its consolidated results of operation, financial position and cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its current or future earnings or operations.

### NOTE 3 FINANCIAL INSTRUMENTS

The Company's financial instruments consist of cash and cash equivalents, accounts receivable, payables and notes payable. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. The carrying amount of the notes payable approximates fair value as the individual borrowings bear interest at rates that approximate market interest rates for similar debt instruments.

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB Accounting Standards Codification (ASC) Topic 820 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

Level 1 - Quoted market prices in active markets for identical assets or liabilities;

Level 2 - Inputs other than level one inputs that are either directly or indirectly observable; and

Level 3 - Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.

Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is observable.

NOTE 4 SUBSEQUENT EVENTS

None.

## Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

### Special Note Regarding Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 (the "Act") provides a safe harbor for forward-looking statements made by or on behalf of our Company. Our Company and our representatives may from time to time make written or oral statements that are forward-looking, including statements contained in this Annual Report and other filings with the Securities and Exchange Commission and in reports to our Company's stockholders. Management believes that all statements that express expectations and projections with respect to future matters, as well as from developments beyond our Company's control including changes in global economic conditions are forward-looking statements within the meaning of the Act. These statements are made on the basis of management's views and assumptions, as of the time the statements are made, regarding future events and business performance. There can be no assurance however, that management's expectations will necessarily come to pass. Factors that may affect forward-looking statements include a wide range of factors that could materially affect future developments and performance, including the following:

·  
Changes in Company-wide strategies, which may result in changes in the types or mix of businesses in which our Company is involved or chooses to invest;

·  
Changes in U.S., global or regional economic conditions;

·  
Changes in U.S. and global financial and equity markets, including significant interest rate fluctuations, which may impede our Company's access to, or increase the cost of, external financing for our operations and investments;

·  
Increased competitive pressures, both domestically and internationally;

·  
Legal and regulatory developments, such as regulatory actions affecting environmental activities;

·  
The imposition by foreign countries of trade restrictions and changes in international tax laws or currency controls;

Adverse weather conditions or natural disasters, such as hurricanes and earthquakes, labor disputes, which may lead to increased costs or disruption of operations.

This list of factors that may affect future performance and the accuracy of forward-looking statements are illustrative, but by no means exhaustive. Accordingly, all forward-looking statements should be evaluated with the understanding of their inherent uncertainty.

#### Critical Accounting Policies and Estimates

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the unaudited Financial Statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from these estimates under different assumptions or conditions. The Company believes there have been no significant changes during the three month period ended March 31, 2017, to the items disclosed as significant accounting policies in management's Notes to the Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2016.

Plan of Operation and Business Growth

Our efforts continue to be focused on increasing the sales of our life science consumables and detectors while, at the same time, working to commercialize our liquid nitrogen refrigeration products. Of those liquid nitrogen refrigeration products, the ultra-low temperature freezer is receiving highest priority. We also continue work on the refrigerated trailer, or reefer. We have our first manufactured unit operational, have conducted a number of road tests and are working to develop alliances with contract manufacturers for those products.

We also continue to focus on the expansion of our detector. We believe that the enhanced functionality of our new detector, coupled with its low cost, provides us with a competitive edge over products currently being sold in that specialized market.

Concurrent with the development and commercialization of the above products, we have completed our on-line catalog and are making progress in enrolling new distributors for our consumable products.

Our revenues during the three month reporting periods decreased 32% during 2017 compared to 2016 revenues.

Results of Operations

Three Months Ended March 31, 2017 and 2016

		For the three months ended March 31,		
		2017	2016	Change
Revenues	\$	255,915\$	373,964\$	(118,049)
Cost of goods sold		90,028	107,180	(17,152)
Gross profit		165,887	266,784	(100,897)
Operating expenses		168,275	230,751	(62,476)
Other expense		-	(143)	143
Net loss	\$	(2,388)\$	35,890\$	(38,278)

Revenues decreased during the quarter ended March 31, 2017, to \$255,915 from \$373,964 for the quarter ended March 31, 2016, a decrease of \$118,049. The decrease results from the sale of ultra-low temperature freezers which generated revenue of \$115,670 in 2016 but only \$27,340 in 2017. We are continuing work to refine and commercialize the ultra-low temperature freezer technologies.

With lower sales during the reporting period, cost of goods decreased in the quarter ending March 31, 2017, as compared to March 31, 2016, to \$90,028 from \$107,180, a decrease of \$17,152. We realized a gross profit percentage of 65% for the three months ended March 31, 2017, compared to 71% for the three months ended March 31, 2016. The gross profit percentage is dependent on the mix of product sales, which varies from quarter to quarter. The ultra-low temperature freezers provide higher gross margins than do our laboratory supplies. We continue to actively work to obtain more favorable pricing from our vendors in order to increase the margins realized on all product lines.

Operating expenses decreased to \$168,276 in the three months ended March 31, 2017, a decrease of \$62,476 over the expenses of \$230,751 incurred in the three month period ended March 31, 2016. The reduction was primarily the result of lower expenditures for research and development of \$15,292 professional fees of \$9,010, inventory adjustments of \$17,372, sales commissions of \$4,170 and license fees of \$5,280. While we continue to monitor and minimize operating costs, we also realize that certain levels of expenditures are required in order to commercialize the products and achieve market penetration.

The net loss for the three month period ended March 31, 2017 was \$2,388, a decrease of \$38,278 from the \$35,890 profit for the three month period ended March 31, 2016. Management continues to look for opportunities to increase sales, improve gross margins and control ongoing operating expenses.

The net loss of \$2,388 for the three month period ended March 31, 2017 represents a loss of \$0.00 per share. This compares to the net profit of \$35,890, or \$0.00 per share for the three months ended March 31, 2016.

#### Seasonality and Cyclicity

We do not believe our business is cyclical.

#### Liquidity and Capital Resources

Our cash resources at March 31, 2017, were \$233,589, with accounts receivable of \$61,328, net of allowance, and inventory of \$232,458, net of allowance. Our working capital on March 31, 2017, was \$505,999. Working capital on December 31, 2016 was \$508,387.

For the three month period ended March 31, 2017, net cash used by operating activities was \$30,375 which compares to \$107,121 net cash provided by operating activities for the three month period ended March 31, 2016.

#### **Off-Balance Sheet Arrangements**

We lease office and warehouse space under a non-cancelable operating lease in Utah which runs through November 30, 2017. Future minimum lease payments under the operating lease at March 31, 2017, are \$24,800 for that facility. In addition, on May 9, 2014, the Company entered into an automobile lease. Future minimum lease payments under this lease are \$2,496 at March 31, 2017, with minimum lease payments of \$2,496 due for the remainder of 2017.

**Item 3. Quantitative and Qualitative Disclosure about Market Risk**

Not required.



#### **Item 4. Controls and Procedures**

(a)

##### **Evaluation of Disclosure Controls and Procedures.**

As of the end of the period covered by this Quarterly Report, we carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon this evaluation, our Chief Executive Officer and Principal Financial Officer concluded that information required to be disclosed is recorded, processed, summarized and reported within the specified periods, and is accumulated and communicated to management, including our Chief Executive Officer and Principal Financial Officer, to allow for timely decisions regarding required disclosure of material information required to be included in our periodic Securities and Exchange Commission reports. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and our Chief Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures are not effective at that reasonable assurance level as of the end of the period covered by this report based upon our current level of transactions and staff. However, it should be noted that the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote

(b)

##### **Changes in Internal Control Over Financial Reporting.**

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act. Management reviewed our internal controls over financial reporting, and there have been no changes in our internal controls over financial reporting for the quarter ended March 31, 2017 that have materially affected, or are like to affect, our internal controls over financial reporting.

## **PART II - OTHER INFORMATION**

### **ITEM 1. Legal Proceedings**

None; not applicable.

**ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds**

**Recent Sales of Unregistered Securities**

None; not applicable.

**Use of Proceeds of Registered Securities**

None; not applicable.

**Purchases of Equity Securities by Us and Affiliated Purchasers**

During the three months ended March 31, 2016, we have not purchased any equity securities nor have any officers or directors of the Company.

**ITEM 3. Defaults Upon Senior Securities**

None

**ITEM 4. Mine Safety Disclosure**

Not applicable.

**ITEM 5. Other Information.**

None

**ITEM 6. Exhibits**

(a)

Exhibits.

Exhibit No. Title of Document

Location if other than attached hereto

Edgar Filing: REFLECT SCIENTIFIC INC - Form 10-Q

3.1	Articles of Incorporation	10-SB Registration Statement*
3.2	Articles of Amendment to Articles of Incorporation	10-SB Registration Statement*
3.3	By-Laws	10-SB Registration Statement*
3.4	Articles of Amendment to Articles of Incorporation	8-K Current Report dated December 31, 2003*
3.5	Articles of Amendment to Articles of Incorporation	8-K Current Report dated December 31, 2003*
3.6	Articles of Amendment	September 30, 2004 10-QSB Quarterly Report*
3.7	By-Laws Amendment	September 30, 2004 10-QSB Quarterly Report*
4.1	Debenture	8-K Current Report dated June 29, 2007*
4.2	Form of Purchasers Warrant	8-K Current Report dated June 29, 2007*
4.3	Registration Rights Agreement	8-K Current Report dated June 29, 2007*
4.4	Form of Placement Agreement	8-K Current Report dated June 29, 2007*
10.1	Securities Purchase Agreement	8-K Current Report dated June 29, 2007*
10.2	Placement Agent Agreement	8-K Current Report dated June 29, 2007*
14	Code of Ethics	December 31, 2003 10-KSB Annual Report*
21	Subsidiaries of the Company	December 31, 2004 10-KSB Annual Report*
31.1	302 Certification of Kim Boyce	
31.2	302 Certification of Keith Merrell	
32	906 Certification	

17

---

**Exhibits**

**Additional Exhibits Incorporated by Reference**

*	Reflect California Reorganization	8-K Current Report dated December 31, 2003
*	JMST Acquisition	8-K Current Report dated April 4, 2006
*	Cryomastor Reorganization	8-K Current Report dated September 27, 2006
*	Image Labs Merger Agreement Signing	8-K Current Report dated November 15, 2006
*	All Temp Merger Agreement Signing	8-K Current Report dated November 17, 2006
*	All Temp Merger Agreement Closing	8-KA Current Report dated November 17, 2006
*	Image Labs Merger Agreement Closing	8-KA Current Report dated November 15, 2006

\* Previously filed and incorporated by reference.

18



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Reflect Scientific, Inc.

(Registrant)

Date:

May 15, 2017

By: /s/ Kim Boyce

Kim Boyce, CEO, President and Director

Date:

May 15, 2017

By: /s/ Tom Tait

Tom Tait, Vice President and Director

Date:

May 15, 2017

By: /s/ Keith Merrell

Keith Merrell, CFO, Principal Financial

Officer

